Viridian Therapeutics (VRDN) to Release Quarterly Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) is set to issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.37). Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.15 million. During the same quarter in the previous year, the firm posted ($1.13) earnings per share. The business's revenue was down 31.4% on a year-over-year basis. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viridian Therapeutics Stock Performance

NASDAQ VRDN traded up $0.55 on Wednesday, hitting $13.81. 1,018,259 shares of the company's stock traded hands, compared to its average volume of 927,330. The company has a current ratio of 18.26, a quick ratio of 18.26 and a debt-to-equity ratio of 0.09. Viridian Therapeutics has a 1-year low of $10.93 and a 1-year high of $28.99. The firm's 50-day moving average price is $16.96 and its two-hundred day moving average price is $17.55. The firm has a market capitalization of $881.38 million, a PE ratio of -2.60 and a beta of 1.07.

Wall Street Analysts Forecast Growth

VRDN has been the subject of several analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $30.00 target price on shares of Viridian Therapeutics in a research note on Wednesday, March 20th. HC Wainwright reissued a "buy" rating and issued a $37.00 price target on shares of Viridian Therapeutics in a report on Thursday, February 29th. B. Riley cut their price target on shares of Viridian Therapeutics from $29.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, March 21st. Finally, Wedbush boosted their price target on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an "outperform" rating in a report on Wednesday, February 28th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $36.60.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.